Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Appetite
Body weight
Diet
Heart failure
Obesity
Weight-loss drug
Journal
Current heart failure reports
ISSN: 1546-9549
Titre abrégé: Curr Heart Fail Rep
Pays: United States
ID NLM: 101196487
Informations de publication
Date de publication:
22 Dec 2023
22 Dec 2023
Historique:
accepted:
13
11
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
aheadofprint
Résumé
Obesity is a major driver of heart failure (HF) incidence, and aggravates its pathophysiology. We summarized key reported and ongoing randomized clinical trials of appetite regulation and/or dietary energy restriction in individuals with HF. Weight loss can be achieved by structured supervised diet programs with behavioural change, medications, or surgery. The new glucagon-like peptide-1 receptor agonists alone or in combination with other agents (e.g., glucose-dependent insulinotropic polypeptide and glucagon receptor agonists or amylin analogues) potently and sustainably reduce appetite, and, taken together with dietary advice, can produce substantial, life-changing, weight loss approaching that achieved by surgery. To date, data from the STEP-HFpEF trial show meaningful improvements in health status (Kansas City Cardiomyopathy Questionnaire). Effective weight management could relieve several drivers of HF, to complement the existing treatments for HF with both reduced and preserved ejection fraction. Further trials of weight loss interventions will provide more definitive evidence to understand their effects on clinical events in patients with HF.
Identifiants
pubmed: 38133864
doi: 10.1007/s11897-023-00637-7
pii: 10.1007/s11897-023-00637-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Reddy YNV, Rikhi A, Obokata M, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020;22(6):1009–18. https://doi.org/10.1002/ejhf.1788 .
doi: 10.1002/ejhf.1788
pubmed: 32150314
Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44(13):1136–53. https://doi.org/10.1093/eurheartj/ehad083 .
doi: 10.1093/eurheartj/ehad083
pubmed: 36944496
pmcid: 10111968
Sattar N, McMurray JJV, McInnes IB, Aroda VR, Lean MEJ. Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes Endocrinol. 2023;11(1):58–62. https://doi.org/10.1016/S2213-8587(22)00317-5 .
doi: 10.1016/S2213-8587(22)00317-5
pubmed: 36460014
Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315(1):36–46. https://doi.org/10.1001/jama.2015.17346 .
doi: 10.1001/jama.2015.17346
pubmed: 26746456
pmcid: 4787295
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. https://doi.org/10.1056/NEJMoa2306963 .
doi: 10.1056/NEJMoa2306963
pubmed: 37622681
Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51. https://doi.org/10.1016/S0140-6736(17)33102-1 .
doi: 10.1016/S0140-6736(17)33102-1
pubmed: 29221645
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183 .
doi: 10.1056/NEJMoa2032183
pubmed: 33567185
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. https://doi.org/10.1056/NEJMoa2206038 .
doi: 10.1056/NEJMoa2206038
pubmed: 35658024
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368 .
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835–78. https://doi.org/10.1016/j.jacc.2023.03.393 .
doi: 10.1016/j.jacc.2023.03.393
pubmed: 37137593
Forsyth F, Mulrennan S, Burt J, et al. What dietary interventions have been tested in heart failure with preserved ejection fraction? A systematic scoping review. Eur J Cardiovasc Nurs. 2023;22(2):126–40. https://doi.org/10.1093/eurjcn/zvac062 .
doi: 10.1093/eurjcn/zvac062
pubmed: 35816028
Brubaker PH, Nicklas BJ, Houston DK, et al. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail. 2023;16(2):e010161. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010161 .
doi: 10.1161/CIRCHEARTFAILURE.122.010161
pubmed: 36314122
McDowell K, Petrie MC, Raihan NA, Logue J. Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obes Rev. 2018;19(9):1189–204. https://doi.org/10.1111/obr.12707 .
doi: 10.1111/obr.12707
pubmed: 30051959
Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77. https://doi.org/10.1002/ejhf.657 .
doi: 10.1002/ejhf.657
pubmed: 27790809
Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8. https://doi.org/10.1001/jama.2016.10260 .
doi: 10.1001/jama.2016.10260
pubmed: 27483064
pmcid: 5021525
Höskuldsdóttir G, Sattar N, Miftaraj M, et al. Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study. J Am Heart Assoc. 2021;10(7):e019323. https://doi.org/10.1161/JAHA.120.019323 .
PHRI. BRAVE. Published 2023. https://www.phri.ca/research/brave/ . Accessed 31 Oct 2023.
Hippocrates. Hippocratic writings. Encyclopedia Britannica. 1955. https://books.google.co.uk/books/about/Hippocratic_Writings.html?id=OxQxzgEACAAJ&redir_esc=y .